BACKGROUND: The role of pleiotrophin and its receptors RPTPβ/ζ and Syndecan-3 during tumor metastasis remains unknown. RESULTS: RPTPβ/ζ knockdown initiates EMT, promotes pleiotrophin-mediated migration and attachment through Syndecan-3 and induces in vivo metastasis. CONCLUSION: RPTPβ/ζ plays a suppressor-like role in prostate cancer metastasis. SIGNIFICANCE: Boosting RPTPβ/ζ or attenuating Syndecan-3 signaling pathways may lead to more effective therapeutic strategies in treating prostate cancer metastasis. Pleiotrophin is a growth factor that induces carcinogenesis. Despite the fact that many published reports focused on the role of pleiotrophin and its receptors, receptor protein tyrosine phosphatase (RPTPβ/ζ), and syndecan-3 during tumor development, no information is available regarding their function in tumor metastasis. To investigate the mechanism through which pleiotrophin regulates tumor metastasis, we used two different prostate carcinoma cell lines, DU145 and PC3, in which the expression of RPTPβ/ζ or syndecan-3 was down-regulated by the RNAi technology. The loss of RPTPβ/ζ expression initiated epithelial-to-mesenchymal transition (EMT) and increased the ability of the cells to migrate and invade. Importantly, the loss of RPTPβ/ζ expression increased metastasis in nude mice in an experimental metastasis assay. We also demonstrate that RPTPβ/ζ counterbalanced the pleiotrophin-mediated syndecan-3 pathway. While the inhibition of syndecan-3 expression inhibited the pleiotrophin-mediated cell migration and attachment through the Src and Fak pathway, the inhibition of RPTPβ/ζ expression increased pleiotrophin-mediated migration and attachment through an interaction with Src and the subsequent activation of a signal transduction pathway involving Fak, Pten, and Erk1/2. Taken together, these results suggest that the loss of RPTPβ/ζ may contribute to the metastasis of prostate cancer cells by inducing EMT and promoting pleiotrophin activity through the syndecan-3 pathway.
BACKGROUND: The role of pleiotrophin and its receptors RPTPβ/ζ and Syndecan-3 during tumor metastasis remains unknown. RESULTS: RPTPβ/ζ knockdown initiates EMT, promotes pleiotrophin-mediated migration and attachment through Syndecan-3 and induces in vivo metastasis. CONCLUSION: RPTPβ/ζ plays a suppressor-like role in prostate cancer metastasis. SIGNIFICANCE: Boosting RPTPβ/ζ or attenuating Syndecan-3 signaling pathways may lead to more effective therapeutic strategies in treating prostate cancer metastasis. Pleiotrophin is a growth factor that induces carcinogenesis. Despite the fact that many published reports focused on the role of pleiotrophin and its receptors, receptor protein tyrosine phosphatase (RPTPβ/ζ), and syndecan-3 during tumor development, no information is available regarding their function in tumor metastasis. To investigate the mechanism through which pleiotrophin regulates tumor metastasis, we used two different prostate carcinoma cell lines, DU145 and PC3, in which the expression of RPTPβ/ζ or syndecan-3 was down-regulated by the RNAi technology. The loss of RPTPβ/ζ expression initiated epithelial-to-mesenchymal transition (EMT) and increased the ability of the cells to migrate and invade. Importantly, the loss of RPTPβ/ζ expression increased metastasis in nude mice in an experimental metastasis assay. We also demonstrate that RPTPβ/ζ counterbalanced the pleiotrophin-mediated syndecan-3 pathway. While the inhibition of syndecan-3 expression inhibited the pleiotrophin-mediated cell migration and attachment through the Src and Fak pathway, the inhibition of RPTPβ/ζ expression increased pleiotrophin-mediated migration and attachment through an interaction with Src and the subsequent activation of a signal transduction pathway involving Fak, Pten, and Erk1/2. Taken together, these results suggest that the loss of RPTPβ/ζ may contribute to the metastasis of prostate cancer cells by inducing EMT and promoting pleiotrophin activity through the syndecan-3 pathway.
Authors: K Meng; A Rodriguez-Peña; T Dimitrov; W Chen; M Yamin; M Noda; T F Deuel Journal: Proc Natl Acad Sci U S A Date: 2000-03-14 Impact factor: 11.205
Authors: Harold Pariser; Laura Ezquerra; Gonzalo Herradon; Pablo Perez-Pinera; Thomas F Deuel Journal: Biochem Biophys Res Commun Date: 2005-07-08 Impact factor: 3.575
Authors: Hans-Jürgen Klomp; Oliver Zernial; Sabine Flachmann; Anton Wellstein; Hartmut Juhl Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: Sabine Müller; Philip Kunkel; Katrin Lamszus; Ulrike Ulbricht; Gustavo Angel Lorente; April Michelle Nelson; David von Schack; Daniel J Chin; Scott Curtis Lohr; Manfred Westphal; Thorsten Melcher Journal: Oncogene Date: 2003-10-02 Impact factor: 9.867
Authors: Sayan Nandi; Mario Cioce; Yee-Guide Yeung; Edward Nieves; Lydia Tesfa; Haishan Lin; Amy W Hsu; Robert Halenbeck; Hui-Yong Cheng; Solen Gokhan; Mark F Mehler; E Richard Stanley Journal: J Biol Chem Date: 2013-06-06 Impact factor: 5.157
Authors: Jihuan Chen; Tomoya Kawamura; Manveen K Sethi; Joseph Zaia; Vez Repunte-Canonigo; Pietro Paolo Sanna Journal: Sci Rep Date: 2017-10-24 Impact factor: 4.379
Authors: Christina Baldauf; Anke Jeschke; Vincent Kanbach; Philip Catala-Lehnen; Daniel Baumhoer; Helwe Gerull; Sophia Buhs; Michael Amling; Peter Nollau; Sheila Harroch; Thorsten Schinke Journal: PLoS One Date: 2015-09-11 Impact factor: 3.240
Authors: Jihuan Chen; Vez Repunte-Canonigo; Tomoya Kawamura; Celine Lefebvre; William Shin; Leonard L Howell; Scott E Hemby; Brandon K Harvey; Andrea Califano; Marisela Morales; George F Koob; Pietro Paolo Sanna Journal: Nat Commun Date: 2013 Impact factor: 14.919